Search
Lucid Diagnostics Inc
LUCDAdd to Watchlist
0.845USD
+0.059+7.51%
Close 09-18 16:00（ET）
161.19MMarket Cap
LossP/E TTM
After-hours 16:25 (ET)0.833USD-0.015-1.77%
After-hours 16:25 (ET)More Details of Lucid Diagnostics Inc Company
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard and EsoCheck. EsoGuard is a bisulfite-converted next generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. It is also developing EsoCure, is an Esophageal Ablation Device, which is a technology that allows a clinician to treat dysplastic BE.
Lucid Diagnostics Inc Profile
Ticker SymbolLUCD
Company nameLucid Diagnostics Inc
IPO dateOct 14, 2021
CEOAklog (Lishan)
Number of employees72
Security typeOrdinary Share
Fiscal year-endOct 14
Address360 Madison Avenue
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10017
Phone12129494319
Websitehttps://www.luciddx.com/
Ticker SymbolLUCD
IPO dateOct 14, 2021
CEOAklog (Lishan)
Company Executives of Lucid Diagnostics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Lishan Aklog, M.D.
Dr. Lishan Aklog, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.64M
-2.06%
Dr. Lishan Aklog, M.D.
Dr. Lishan Aklog, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.64M
-2.06%
Dr. Lishan Aklog, M.D.
Dr. Lishan Aklog, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.64M
-2.06%
Dr. James L. Cox, M.D.
Dr. James L. Cox, M.D.
Independent Director
Independent Director
405.12K
--
Dr. James L. Cox, M.D.
Dr. James L. Cox, M.D.
Independent Director
Independent Director
405.12K
--
Dr. James L. Cox, M.D.
Dr. James L. Cox, M.D.
Independent Director
Independent Director
405.12K
--
Mr. Stanley N. Lapidus
Mr. Stanley N. Lapidus
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
337.39K
--
Mr. Stanley N. Lapidus
Mr. Stanley N. Lapidus
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
337.39K
--
Mr. Stanley N. Lapidus
Mr. Stanley N. Lapidus
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
337.39K
--
Dr. Jacque J. Sokolov, M.D.
Dr. Jacque J. Sokolov, M.D.
Independent Director
Independent Director
320.46K
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Lishan Aklog, M.D.
Dr. Lishan Aklog, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.64M
-2.06%
Dr. Lishan Aklog, M.D.
Dr. Lishan Aklog, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.64M
-2.06%
Dr. Lishan Aklog, M.D.
Dr. Lishan Aklog, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.64M
-2.06%
Dr. James L. Cox, M.D.
Dr. James L. Cox, M.D.
Independent Director
Independent Director
405.12K
--
Dr. James L. Cox, M.D.
Dr. James L. Cox, M.D.
Independent Director
Independent Director
405.12K
--
Dr. James L. Cox, M.D.
Dr. James L. Cox, M.D.
Independent Director
Independent Director
405.12K
--
FAQs
Who are the top five shareholders of Lucid Diagnostics Inc?
The top five shareholders of Lucid Diagnostics Inc are: Dr. Lishan Aklog, M.D.
How many institutions hold shares of Lucid Diagnostics Inc (LUCD)?
As of 2026Q1, 167 institutions hold shares of Lucid Diagnostics Inc, with a combined market value of approximately 39.22M, accounting for 20.09% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 2215098.00.